Aurobindo Pharma climbs after USFDA nod for OTC drug

Shares of Aurobindo Pharma surged over 2 per cent today after the firm got final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for treatment of osteoporosis.
The stock soared 2.31 per cent to Rs 738 on BSE.
On NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg," Aurobindo Pharma had said in a BSE filing on Saturday.
"The product is expected to be launched in Q1 of 2016-17," it had said.